




Instance: composition-en-9b714872ced428c978b15edf78a3a6b4
InstanceOf: CompositionUvEpi
Title: "Composition for circadin Package Leaflet"
Description:  "Composition for circadin Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "identifier"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mp61ab6e13a68691fed66e52cea007962f)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - circadin"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #en
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What is in this leaflet:</p>
<ol>
<li>What Circadin is and what it is used for </li>
<li>What you need to know before you take Circadin </li>
<li>How to take Circadin </li>
<li>Possible side effects </li>
<li>How to store Circadin </li>
<li>Contents of the pack and other information </li>
</ol>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What circadin is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What circadin is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>The active substance of Circadin, melatonin, belongs to a natural group of hormones produced by the 
body. </p>
<p>Circadin is used on its own for the short-term treatment of primary insomnia (persistent difficulty in 
getting to sleep or staying asleep, or poor quality of sleep) in patients aged 55 years and older. 
 Primary  means that the insomnia does not have any identified cause, including any medical, mental 
or environmental cause. </p>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take circadin"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take circadin"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Do not take Circadin 
- if you are allergic to melatonin or any of the other ingredients of this medicine (listed in 
section 6). </p>
<p>Warnings and precautions 
Talk to your doctor or pharmacist before taking Circadin. </p>
<ul>
<li>If you suffer from liver or kidney problems. No studies on the use of Circadin in people with 
liver or kidney diseases have been performed, you should speak to your doctor before taking 
Circadin as its use is not recommended. </li>
<li>If you have been told by your doctor that you have an intolerance to some sugars. </li>
<li>If you have been told you suffer from an autoimmune disease (where the body is  attacked  by 
its own immune system). No studies on the use of Circadin in people with auto-immune 
diseases have been performed; therefore, you should speak to your doctor before taking 
Circadin as its use is not recommended. </li>
<li>Circadin can make you feel drowsy, you should be careful if the drowsiness affects you as it 
may impair your ability on tasks such as driving. </li>
<li>Smoking may make Circadin less effective, because the components of tobacco smoke can 
increase the breakdown of melatonin by the liver. 
Children and adolescents 
Do not give this medicine to children between the ages of 0 to 18 years as it has not been tested and its 
effects are unknown. Another medicine containing melatonin may be more appropriate for 
administration to children between the ages of 2 to 18 - please ask your doctor or pharmacist for 
advice. </li>
</ul>
<p>Other medicines and Circadin 
Tell your doctor or pharmacist if you are taking, have recently taken or might take any other 
medicines.  These medicines include: </p>
<p>Fluvoxamine (used for the treatment of depression and obsessive compulsive disorder), 
psoralens (used in the treatment of skin disorders e.g. psoriasis), cimetidine (used in the 
treatment of stomach problems such as ulcers), quinolones and rifampicin (used in the treatment 
of bacterial infections), oestrogens (used in contraceptives or hormone replacement therapy) and 
carbamazepine (used in the treatment of epilepsy). </p>
<p>Adrenergic agonists/antagonists (such as certain types of medicines used to control blood 
pressure by constricting blood vessels, nasal decongestants, blood pressure lowering medicines), 
opiate agonists/antagonists (such as medicinal products used in the treatment of drug addiction), 
prostaglandin inhibitors (such as nonsteroidal anti-inflammatory medicines), antidepressant 
medication, tryptophan and alcohol. </p>
<p>Benzodiazepines and non-benzodiazepine hypnotics (medicines used to induce sleep such as 
zaleplon, zolpidem and zopiclone) </p>
<p>Thioridazine (for the treatment of schizophrenia) and imipramine (for the treatment of 
depression). </p>
<p>Circadin with food, drink and alcohol 
Take Circadin after you have eaten.  Do not drink alcohol before, during or after taking Circadin, 
because it reduces the effectiveness of Circadin. </p>
<p>Pregnancy and breast-feeding 
Do not take Circadin if you are pregnant, think you may be pregnant, trying to become pregnant or 
breast-feeding.  Ask your doctor or pharmacist for advice before taking this medicine. </p>
<p>Driving and using machines 
Circadin may cause drowsiness.  If you are affected, you should not drive or operate machinery.  If 
you suffer from continued drowsiness, then you should consult your doctor. </p>
<p>Circadin contains lactose monohydrate. 
Circadin contains lactose monohydrate.  If you have been told by your doctor that you have an 
intolerance to some sugars, contact your doctor before taking this medicinal product. </p>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take circadin"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take circadin"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Always take this medicine exactly as your doctor or pharmacist has told you.  Check with your doctor 
or pharmacist if you are not sure. </p>
<p>The recommended dose is one Circadin tablet (2 mg) taken daily by mouth, after food, 1-2 hours 
before bedtime. This dosage may be continued for up to thirteen weeks. </p>
<p>You should swallow the tablet whole.  Circadin tablets should not be crushed or cut in half. </p>
<p>If you take more Circadin than you should 
If you have accidentally taken too much of your medicine, contact your doctor or pharmacist as soon 
as possible. </p>
<p>Taking more than the recommended daily dose may make you feel drowsy. </p>
<p>If you forget to take Circadin 
If you forget to take your tablet, take another as soon as you remember, before going to sleep, or wait 
until it is time to take your next dose, then go on as before. </p>
<p>Do not take a double dose to make up for a forgotten dose. </p>
<p>If you stop taking Circadin 
There are no known harmful effects if treatment is interrupted or ended early.  The use of Circadin is 
not known to cause any withdrawal effects after treatment completion. </p>
<p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist. </p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Like all medicines, this medicine can cause side effects, although not everybody gets them. </p>
<p>If you experience any of the following serious side effects, stop taking the medicine and contact your 
doctor immediately:-<br />
Uncommon: (may affect up to 1 in 100 people) </p>
<p>Chest pain </p>
<p>Rare: (may affect up to 1 in 1000 people) </p>
<p>Loss of consciousness or fainting </p>
<p>Severe chest pain due to angina </p>
<p>Feeling your heartbeat </p>
<p>Depression </p>
<p>Visual impairment </p>
<p>Blurred vision </p>
<p>Disorientation </p>
<p>Vertigo (a feeling of dizziness or  spinning ) </p>
<p>Presence of red blood cells in the urine </p>
<p>Reduced number of white blood cells in the blood </p>
<p>Reduced blood platelets, which increases risk of bleeding or bruising </p>
<p>psoriasis </p>
<p>If you experience any of the following non-serious side effects contact your doctor and/or seek 
medical advice:-<br />
Uncommon: (may affect up to 1 in 100 people) </p>
<p>Irritability, nervousness, restlessness, insomnia, abnormal dreams, nightmares, anxiety, migraine, 
headache, lethargy (tiredness, lack of energy), restlessness associated with increased activity, 
dizziness, tiredness, high blood pressure, upper abdominal pain, indigestion, mouth ulceration, dry 
mouth, nausea, changes in the composition of your blood which could cause yellowing of the skin or 
eyes, inflammation of the skin, night sweats, itching, rash, dry skin, pain in extremities, menopausal 
symptoms, feeling of weakness, excretion of glucose in the urine, excess proteins in the urine, 
abnormal liver function and weight increase. </p>
<p>Rare: (may affect up to 1 in 1000 people) </p>
<p>Shingles, high level of fatty molecules in the blood, low serum calcium levels in the blood, low 
sodium levels in the blood, altered mood, aggression, agitation, crying, stress symptoms, early 
morning awakening, increased sex drive, depressed mood,  memory impairment, disturbance in 
attention, dreamy state, restless legs syndrome, poor quality sleep,  pins and needles  feeling, watery 
eyes, dizziness when standing or sitting, hot flushes, acid reflux, stomach disorder, blistering in the 
mouth, tongue ulceration, stomach upset, vomiting, abnormal bowel sounds, wind, excess saliva 
production, bad breath, abdominal discomfort, gastric disorder, inflammation of the stomach lining, 
eczema, skin rash, hand dermatitis, itchy rash, nail disorder, arthritis, muscle spasms, neck pain, night 
cramps, prolonged erection that might be painful, inflammation of the prostate gland, tiredness, pain, 
thirst, passing large volumes of urine, urinating during the night, increased liver enzymes, abnormal 
blood electrolytes and abnormal laboratory tests. </p>
<p>Frequency not known: (cannot be established from the available data) </p>
<p>Hypersensitivity reaction, swelling of mouth or tongue, swelling of the skin and abnormal milk 
secretion. </p>
<p>Reporting of side effects 
If you get any side effects, talk to your doctor or pharmacist.  This includes any possible side effects 
not listed in this leaflet.  You can also report side effects directly via the national reporting system 
listed in Appendix V.  By reporting side effects you can help provide more information on the safety 
of this medicine. </p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store circadin"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store circadin"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Keep this medicine out of the sight and reach of children. </p>
<p>Do not use this medicine after the expiry date which is stated on the carton (EXP).  The expiry date 
refers to the last day of that month. </p>
<p>Do not store above 25 C.  Store in the original package in order to protect from light. </p>
<p>Do not throw away any medicines via wastewater or household waste.  Ask your pharmacist how to 
throw away medicines you no longer use.  These measures will help to protect the environment. </p>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What Circadin contains 
- The active substance is melatonin.  Each prolonged-release tablet contains 2 mg melatonin. 
- The other ingredients are ammonio methacrylate copolymer type B, calcium hydrogen 
phosphate dihydrate, lactose monohydrate, silica (colloidal anhydrous), talc and magnesium 
stearate. </p>
<p>What Circadin looks like and contents of the pack 
Circadin 2 mg prolonged-release tablets are available as white to off-white round bi-convex shaped 
tablets.  Each carton of tablets contains one blister strip of 7, 20 or 21 tablets, or alternatively in a 
carton containing two blister strips of 15 tablets each (30 tablet pack).  Not all pack sizes may be 
marketed. </p>
<p>Marketing Authorisation Holder and Manufacturer </p>
<p>Marketing Authorisation Holder: </p>
<p>RAD Neurim Pharmaceuticals EEC SARL 
4 rue de Marivaux 
75002 Paris 
France 
e-mail: regulatory@neurim.com </p>
<p>Manufacturer: </p>
<p>Sites responsible for Batch Release in the EEA:-<br />
Temmler Pharma GmbH &amp; Co. KG 
Temmlerstrasse 2 
35039 Marburg 
Germany </p>
<p>Iberfar Ind stria Farmac utica S.A. 
Estrada Consiglieri Pedroso Queluz De Baixo 
Barcarena 
2734-Portugal </p>
<p>Rovi Pharma Industrial Services, S.A. 
V a Complutense, Alcal  de Henares 
Madrid, 28Spain </p>
<p>For any information about this medicine, please contact the local representative of the Marketing 
Authorisation Holder </p>
<p>Belgi /Belgique/Belgien 
Takeda Belgium 
T l/Tel: +32 2 464 06 e-mail: medinfoEMEA@takeda.com </p>
<p>Lietuva 
RAD Neurim Pharmaceuticals EEC SARL 
Tel: +33 185149776 (FR) 
e-mail: neurim@neurim.com </p>
<p>RAD Neurim Pharmaceuticals EEC SARL 
Te : +33 185149776 (FR) 
e-mail: neurim@neurim.com </p>
<p>Luxembourg/Luxemburg 
Takeda Belgium 
T l/Tel: +32 2 464 06 11 (BE) 
e-mail: medinfoEMEA@takeda.com </p>
<p>esk  republika 
RAD Neurim Pharmaceuticals EEC SARL 
Tel: +33 185149776 (FR) 
e-mail: neurim@neurim.com 
Magyarorsz g 
RAD Neurim Pharmaceuticals EEC SARL 
Tel: +33 185149776 (FR) 
e-mail: neurim@neurim.com </p>
<p>Danmark 
Takeda Pharma A/S 
Tlf: +45 46 77 11 Malta 
RAD Neurim Pharmaceuticals EEC SARL 
Tel: +33 185149776 (FR) 
e-mail: neurim@neurim.com </p>
<p>Deutschland 
INFECTOPHARM Arzneimittel<br />
und Consilium GmbH 
Tel: +49 6252 957e-mail: kontakt@infectopharm.com </p>
<p>Nederland 
Takeda Nederland bv 
Tel: +31 20 203 5e-mail: medinfoEMEA@takeda.com </p>
<p>Eesti 
RAD Neurim Pharmaceuticals EEC SARL 
Tel: +33 185149776 (FR) 
e-mail: neurim@neurim.com </p>
<p>Norge 
Takeda AS 
Tlf: +47 800 800 e-mail: medinfoEMEA@takeda.com </p>
<p>TAKEDA    . . 
 : +30 210 6387e-mail: medinfoEMEA@takeda.com </p>
<p>sterreich 
SANOVA PHARMA GesmbH 
Tel.: +43 (01) 80104-0 
e-mail: sanova.pharma@sanova.at </p>
<p>Espa a 
EXELTIS HEALTHCARE, S.L. 
Tfno: +34 91 7711Polska 
MEDICE Arzneimittel P tter GmbH &amp; Co. KG<br />
Tel.: + 48-(0)22 642 2e-mail: office@medice.pl </p>
<p>France 
BIOCODEX 
T l: +33 (0)1 41 24 30 e-mail: medinfo@biocodex.com </p>
<p>Portugal 
Italfarmaco, Produtos Farmac uticos, Lda. 
Tel. +351 214 342 e-mail: geral@itf-farma.pt </p>
<p>Hrvatska 
RAD Neurim Pharmaceuticals EEC SARL 
Tel: +33 185149776 (FR) 
e-mail: neurim@neurim.com </p>
<p>Rom nia 
RAD Neurim Pharmaceuticals EEC SARL 
Tel: +33 185149776 (FR) 
e-mail: neurim@neurim.com </p>
<p>Ireland 
RAD Neurim Pharmaceuticals EEC SARL 
Tel: +33 185149776 (FR) 
e-mail: neurim@neurim.com </p>
<p>Slovenija 
RAD Neurim Pharmaceuticals EEC SARL 
Tel: +33 185149776 (FR) 
e-mail: neurim@neurim.com </p>
<p>sland 
Vistor hf. 
S mi: +354 535 7Slovensk  republika 
RAD Neurim Pharmaceuticals EEC SARL 
Tel: +33 185149776 (FR) 
e-mail: neurim@neurim.com </p>
<p>Italia 
Fidia Farmaceutici S.p.A. 
Tel: +39 049 8232e-mail: info@fidiapharma.it </p>
<p>Suomi/Finland 
Takeda Oy<br />
Puh/Tel: +358 20 746 5<br />
RAD Neurim Pharmaceuticals EEC SARL 
  : +33 185149776 (FR) 
e-mail: neurim@neurim.com </p>
<p>Sverige 
Takeda Pharma AB 
Tel: +46 8 731 28 e-mail: medinfoEMEA@takeda.com </p>
<p>Latvija 
RAD Neurim Pharmaceuticals EEC SARL 
Tel: +33 185149776 (FR) 
e-mail: neurim@neurim.com </p>
<p>United Kingdom (Northern Ireland) 
RAD Neurim Pharmaceuticals EEC SARL 
Tel: +33 185149776 (FR) 
e-mail: neurim@neurim.com </p>
<p>This leaflet was last revised in { month/YYYY}. </p>
<p>Other sources of information </p>
<p>Detailed information on this medicine is available on the European Medicines Agency web site: </p>         </div>"""      



Instance: composition-da-9b714872ced428c978b15edf78a3a6b4
InstanceOf: CompositionUvEpi
Title: "Composition for circadin Package Leaflet"
Description:  "Composition for circadin Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "identifier"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mp61ab6e13a68691fed66e52cea007962f)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - circadin"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #da
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Oversigt over indlægssedlen: 
1. Virkning og anvendelse 
2. Det skal du vide, før du begynder at tage Circadin 
3. Sådan skal du tage Circadin 
4. Bivirkninger 
5. Opbevaring 
6. Pakningsstørrelser og yderligere oplysninger </p>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What circadin is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What circadin is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Det aktive stof i Circadin, melatonin, hører til en naturlig gruppe af hormoner, som kroppen selv 
danner. </p>
<p>Circadin anvendes som monoterapi (et enkelt lægemiddel) til korttidsbehandling af primær søvnløshed 
(vedvarende vanskelighed ved at falde i søvn eller blive ved med at sove eller dårlig søvnkvalitet) hos 
patienter i alderen 55 år og derover. "Primær" vil sige, at søvnløsheden ikke har nogen identificeret 
årsag, hverken medicinsk, psykisk eller miljømæssig årsag. </p>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take circadin"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take circadin"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Tag ikke Circadin 
- hvis du er allergisk over for melatonin eller et af de øvrige indholdsstoffer i denne medicin 
(angivet i pkt. 6). </p>
<p>Advarsler og forsigtighedsregler 
Kontakt lægen eller apoteket, før du tager Circadin. </p>
<ul>
<li>Hvis du lider af lever- eller nyreproblemer. Der er ikke gennemført undersøgelser af brugen af 
Circadin hos personer med lever- eller nyresygdomme, du bør tale med din læge, før du tager 
Circadin, da det ikke kan anbefales at anvende det. </li>
<li>Hvis du har fået at vide af din læge, at du har en intolerans over for visse sukkerarter. </li>
<li>Hvis du har fået at vide, at du lider af en autoimmun sygdom (hvor kroppen ’angribes’ af sit 
eget immunsystem). Der er ikke gennemført undersøgelser af brugen af Circadin hos personer 
med autoimmun-sygdpmme, derfor skal du tale med din læge, før du tager Circadin, da det ikke 
kan anbefales at anvende det. </li>
<li>Circadin kan få dig til at føle dig døsig, du skal være forsigtig, his døsigheden påvirker dig, da 
det kan nedsætte din evne til fx at køre bil. </li>
<li>Rygning kan gøre circadin mindre effektivt, fordi indholdsstofferne i tobaksrøg kan øge 
leverens nedbrydning af melatonin. </li>
</ul>
<p>Børn og unge 
Denne medicin må ikke gives til børn og teenagere mellem 0 og 18 år, da det ikke er testet på dem, og 
dets virkninger på dem ikke er kendt. E andet lægemiddel indeholdende melatonin kan være mere 
passende til indgift hos børn i alderen 2 til 18 år - søg rådgivning hos din læge eller 
apotekespersonalet. </p>
<p>Brug af anden medicin sammen med Circadin 
Fortæl altid lægen eller på apoteket, hvis du bruger anden medicin eller har gjort det for nylig. Dette 
gælder også medicin, som ikke er købt på recept, f.eks. naturlægemidler og vitaminer og mineraler. 
Disse lægemidler omfatter:</p>
<ul>
<li>Fluvoxamin (bruges til behandling af depression og obsessiv-kompulsiv tilstand OCD), 
psoralener (anvendes til behandling af hudproblemer, fx psoriasis), cimetidin (brugs til 
behandling af maveproblemer, som fx mavesår), quinoloner og rifampicin (bruges til 
behandling af bakterieinfektioner), østrogener (bruges i præventionsmidler eller 
hormonsubstitutionsbehandling) og carbamazepin (bruges til behandling af epilepsi). </li>
<li>Adrenerge agonister/antagonister (som fx. visse typer medicin, der bruges til at kontrollere 
blodtrykket ved at  indsnævre blodkarrene, midler mod tilstoppet næse, blodtrykssænkende 
medicin), opiate agonister/antagonister (som fx ikke-steroide anti-inflammatoriske lægemidler), 
antidepressive midler, tryptophan og alkohol. </li>
<li>Benzodiazepiner og hypnotika uden benzodiazepin (indsovningsmedicin som fx zaleplon, 
zolpidem og zopliclon) </li>
<li>Thioridazin (til behandling af skizofreni) og imipramin (til behandling af depression). </li>
</ul>
<p>Brug af Circadin sammen med mad, drikke og alkohol 
Tag Circadin efter, at du har spist. Drik ikke alkohol før, under eller efter, du har taget Circadin, da det 
mindsker virkningen af Circadin. </p>
<p>Graviditet, amning og frugtbarhed 
Hvis du er gravid eller ammer, har mistanke om, at du er gravid eller planlægger at blive gravid, skal 
du spørge din læge eller apotekspersonalet til råds, før du tager dette lægemiddel. </p>
<p>Trafik- og arbejdssikkerhed 
Circadin kan medføre døsighed. Hvis du er døsig, bør du ikke køre bil eller betjene maskiner. Hvis du 
lider af vedvarende døsighed, skal du spørge din læge til råds. </p>
<p>Circadin indeholder lactosemonohydrat 
Circadin indeholder lactosemonohydrat. Hvis din læge har fortalt dig, at der er visse sukkertyper, du 
ikke kan tåle, bør du kontakte din læge, før du tager dette lægemiddel. </p>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take circadin"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take circadin"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Tag altid dette lægemiddel nøjagtigt efter lægens eller apotekspersonalets anvisning. Er du i tvivl, så 
spørg lægen eller på apoteket. </p>
<p>Den anbefalede dosis er én Circadin-tablet (2 mg) taget daglig gennem munden, efter mad, 1-2 timer 
inden sengetid. Du kan fortsætte med at tage denne dosis i op til tretten uger. </p>
<p>Du skal synke tabletterne hele. Circadin-tabletter må ikke knuses eller deles i to dele. </p>
<p>Hvis du har taget for meget Circadin 
Hvis du er kommet til at tage for meget medicin, skal du hurtigst muligt kontakte din læge eller 
apoteket. </p>
<p>Hvis du tager mere end den anbefalede daglige dosis, kan du føle dig døsig. </p>
<p>Hvis du har glemt at tage Circadin 
Hvis du glemmer at tage din tablet, skal du tage én, så snart du kommer i tanker om det, før du går i 
seng, eller vente til det er tid for næste dosis. Fortsæt derefter som før. </p>
<p>Du må ikke tage en dobbeltdosis som erstatning for den glemte tablet. </p>
<p>Hvis du holder op med at tage Circadin 
Der er ingen kendte skadelige virkninger, hvis behandlingen afbrydes eller afsluttes før tiden. Brugen 
af Circadin menes ikke at give abstinenser efter, at behandlingen er afsluttet. </p>
<p>Spørg lægen eller apotekspersonalet, hvis der er noget, du er tvivl om eller føler dig usikker på med 
hensyn til brugen af denne medicin. </p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Dette lægemiddel kan som al anden medicin give bivirkninger, men ikke alle får bivirkninger. </p>
<p>Hvis du oplever nogen af følgende alvorlige bivirkninger, skal du ophøre med at tage medicinen og 
omgående kontakre din læge.: </p>
<p>Ikke almindelige: (kan forekomme hos op til 1 ud af 100 personer) </p>
<ul>
<li>Brystsmerter </li>
</ul>
<p>Sjældne: (kan forekomme hos op til 1 ud af 1000 personer) </p>
<ul>
<li>
<p>Tab af bevidsthed eller besvimelse </p>
</li>
<li>
<p>Alvorlige brystsmerter på grund af angina </p>
</li>
<li>
<p>Følelse af hjertebanken </p>
</li>
<li>
<p>Depression </p>
</li>
<li>
<p>Nedsat syn </p>
</li>
<li>
<p>Uklart syn </p>
</li>
<li>
<p>Desorientering </p>
</li>
<li>
<p>Vertigo (en følelse af svimmelhed, "det hele snurrer rundt") </p>
</li>
<li>
<p>Tilstedeværelse af røde blodceller i urinen </p>
</li>
<li>
<p>Nedsat antal hvide blodlegemer i blodet </p>
</li>
<li>
<p>Nedsat antal blodplader, hvilket øger risikoen for blødning eller blå mærker </p>
</li>
<li>
<p>Psoriasis </p>
</li>
</ul>
<p>Hvis du oplever nogen af følgende ikke-alvorlige bivirkninger, børf du kontakte din læge og/eller 
sæge lægehjælp: </p>
<p>Ikke almindelige: (kan forekomme hos op til 1 ud af 100 personer) </p>
<p>Irritabilitet, nervøsitet, rastløshed, søvnløshed, abnorme drømme, mareridt, angst, migræne, 
hovedpine, letargi (træthed, mangel på energi), rastløshed i forbindelse med øget aktivitet, 
svimmelhed, døsighed, forhøjet blodtryk, mavepine, fordøjelsesbesvær, mundsår, mundtørhed, 
kvalme, forandringer i sammensætningen af dit blod, som kan medføre, at huden eller det hvide i 
øjnene bliver farvet gul, betændelse i huden, natlige svedeture, kløe, udslæt, tør hud, smerter i arme og 
ben, symptomer på overgangsalder, følelse af svaghed,  udskillelse af glukose  i urinen, for meget 
protein i urinen, unormal leverfunktion og vægtforøgelse. </p>
<p>Sjældne: (kan forekomme hos op til 1 ud af 1000 personer) </p>
<p>Helvedesild, et højt niveau af fedt i blodet, lave niveauer af kalcium i blodet, lave niveauer af natrium 
i blodet, humørændringer, aggression, rastløs uro, gråd, stresssymptomer, tidlig opvågning om 
morgenen, øget sexlyst, nedtrykt sindstilstand, nedsat hukommelse, opmærksomhedsforstyrrelse, 
drømmende sindstilstand, uro i benene, dårlig søvnkvalitet, en prikkende og stikkende fornemmelse i 
huden, rindende øjne, svimmelhed i stående eller siddende stilling, hedeture, halsbrand og sure opstød, 
maveproblemer, blister i munden, sårdannelse på tungen, mavebesvær, opkastning, unormale 
tarmlyde, luft fra tarmen, overdreven spytdannelse, dårlig ånde, mavebesvær, lidelse i mavesækken, 
betændelse i mavesækken, eksem, hududslæt, udslæt på hænderne, kløende udslæt, negleproblemer, 
ledsmerter, muskelkramper, nakkesmerter, nattekramper, forlænget erektionsvarighed, hvilket kan 
være smertefuldt, betændelse i blærehalskirtlen, træthed, smerter, tørst, voldsom vandladning, natlig 
vandladning, forhøjede leverenzymer, unormale blodelektrolytter og unormale laboratorieprøver. </p>
<p>Hyppighed ikke kendt: (kan ikke fastsættes ud fra de tilgængelige data) </p>
<p>Overfølsomhedsreaktion, hævelse af mund eller tunge, hævelse af huden og unormalt mælkesekret. </p>
<p>Indberetning af bivirkninger 
Hvis du får oplever bivirkninger, bør du tale med din læge, sygeplejerske eller apoteket. Dette gælder 
også mulige bivirkninger, som ikke er medtaget i denne indlægsseddel. Du eller dine pårørende kan 
også indberette bivirkninger direkte til Sundhedsstyrelsen det nationale rapporteringssystem anført i 
Appendiks V. Ved at indrapportere bivirkninger kan du hjælpe med at fremskaffe mere information 
om sikkerheden ved dette lægemiddel. </p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store circadin"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store circadin"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Opbevares utilgængeligt for børn. </p>
<p>Brug ikke dette lægemiddel efter den udløbsdato, der står på pakningen. Udløbsdatoen er den sidste 
dag i den nævnte måned. </p>
<p>Må ikke opbevares ved temperaturer over 25°C. Opbevares i den originale emballage for at beskytte 
mod lys. </p>
<p>Spørg på apoteket, hvordan du skal bortskaffe medicinrester. Af hensyn til miljøet må du ikke smide 
medicinrester i afløbet, toilettet eller skraldespanden. </p>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Circadin indeholder:</p>
<ul>
<li>Aktivt stof/aktive stoffer: melatonin. Hver depottablet indeholder 2 mg melatonin. </li>
<li>Øvrige indholdsstoffer (hjælpestoffer): Ammoniummethacrylat copolymer (type B), 
Calciumhydrogenphosphatdihydrat, lactosemonohydrat, vandfri, kolloid silica, talcum og 
magnesiumstearat. </li>
</ul>
<p>Udseende og pakningsstørrelser 
Circadin 2 mg depottabletter fås som hvide til off-white, runde, bikonvekse tabletter. Hver æske 
indeholder en blisterstrip med 7, 20 eller 21 tabletter eller alternativt to blisterstrips med hver 
15 tabletter (i alt 30 tabletter i æsken). Ikke alle pakningsstørrelser er nødvendigvis markedsført. </p>
<p>Indehaver af markedsføringstilladelsen og fremstiller </p>
<p>Indehaver af markedsføringstilladelsen: </p>
<p>RAD Neurim Pharmaceuticals EEC SARL 
4 rue de Marivaux 
75002 Paris 
Frankrig 
e-mail: regulatory@neurim.com </p>
<p>Fremstiller: </p>
<p>Fremstillerne ansvarlige for batchfrigivelse i EEA: </p>
<p>Temmler Pharma GmbH &amp; Co. KG 
Temmlerstrasse 2 
35039 Marburg 
Tyskland </p>
<p>Iberfar Indústria Farmacêutica S.A. 
Estrada Consiglieri Pedroso Queluz De Baixo 
Barcarena 
2734-Portugal </p>
<p>Rovi Pharma Industrial Services, S.A. 
Vía Complutense, Alcalá de Henares 
Madrid, 28Spanien </p>
<p>Hvis du ønsker yderligere oplysninger om dette lægemiddel, skal du henvende dig til den lokale 
repræsentant for indehaveren af markedsføringstilladelsen: </p>
<p>België/Belgique/Belgien 
Takeda Belgium 
Tél/Tel: +32 2 464 06 e-mail: medinfoEMEA@takeda.com 
Lietuva 
RAD Neurim Pharmaceuticals EEC SARL 
Tel: +33 185149776 (FR) 
e-mail: neurim@neurim.com </p>
<p>България 
RAD Neurim Pharmaceuticals EEC SARL 
Teл: +33 185149776 (FR) 
e-mail: neurim@neurim.com </p>
<p>Luxembourg/Luxemburg 
Takeda Belgium 
Tél/Tel: +32 2 464 06 11 (BE) 
e-mail: medinfoEMEA@takeda.com </p>
<p>Česká republika 
RAD Neurim Pharmaceuticals EEC SARL 
Tel: +33 185149776 (FR) 
e-mail: neurim@neurim.com </p>
<p>Magyarország 
RAD Neurim Pharmaceuticals EEC SARL 
Tel: +33 185149776 (FR) 
e-mail: neurim@neurim.com </p>
<p>Danmark 
Takeda Pharma A/S 
Tlf: +45 46 77 11<br />
Malta 
RAD Neurim Pharmaceuticals EEC SARL 
Tel: +33 185149776 (FR) 
e-mail: neurim@neurim.com </p>
<p>Deutschland 
INFECTOPHARM Arzneimittel<br />
und Consilium GmbH 
Tel: +49 6252 957e-mail: kontakt@infectopharm.com </p>
<p>Nederland 
Takeda Nederland bv 
Tel: +31 20 203 5e-mail: medinfoEMEA@takeda.com </p>
<p>Eesti 
RAD Neurim Pharmaceuticals EEC SARL 
Tel: +33 185149776 (FR) 
e-mail: neurim@neurim.com </p>
<p>Norge 
Takeda AS 
Tlf: +47 800 800 e-mail: medinfoEMEA@takeda.com </p>
<p>Ελλάδα 
TAKEDA ΕΛΛΑΣ Α.Ε. 
Τηλ: +30 210 6387e-mail: medinfoEMEA@takeda.com </p>
<p>Österreich 
SANOVA PHARMA GesmbH 
Tel.: +43 (01) 80104-0 
e-mail: sanova.pharma@sanova.at </p>
<p>España 
EXELTIS HEALTHCARE, S.L. 
Tfno: +34 91 7711 
Polska 
MEDICE Arzneimittel Pütter GmbH &amp; Co. KG<br />
Tel.: + 48-(0)22 642 2e-mail: office@medice.pl </p>
<p>France 
BIOCODEX 
Tél: +33 (0)1 41 24 30 e-mail: medinfo@biocodex.com </p>
<p>Portugal 
Italfarmaco, Produtos Farmacêuticos, Lda. 
Tel. +351 214 342 e-mail: geral@itf-farma.pt </p>
<p>Hrvatska 
RAD Neurim Pharmaceuticals EEC SARL 
Tel: +33 185149776 (FR) 
e-mail: neurim@neurim.com </p>
<p>România 
RAD Neurim Pharmaceuticals EEC SARL 
Tel: +33 185149776 (FR) 
e-mail: neurim@neurim.com </p>
<p>Ireland 
RAD Neurim Pharmaceuticals EEC SARL 
Tel: +33 185149776 (FR) 
e-mail: neurim@neurim.com </p>
<p>Slovenija 
RAD Neurim Pharmaceuticals EEC SARL 
Tel: +33 185149776 (FR) 
e-mail: neurim@neurim.com </p>
<p>Ísland 
Vistor hf. 
Simi: +354 535 7 
Slovenská republika 
RAD Neurim Pharmaceuticals EEC SARL 
Tel: +33 185149776 (FR) 
e-mail: neurim@neurim.com </p>
<p>Italia 
Fidia Farmaceutici S.p.A. 
Tel: +39 049 8232e-mail: info@fidiapharma.it </p>
<p>Suomi/Finland 
Takeda Oy 
Puh/Tel: +358 20 746 5 
Κύπρος 
RAD Neurim Pharmaceuticals EEC SARL 
Τηλ : +33 185149776 (FR) 
e-mail: neurim@neurim.com </p>
<p>Sverige 
Takeda Pharma AB 
Tel: +46 8 731 28 e-mail: medinfoEMEA@takeda.com </p>
<p>Latvija 
RAD Neurim Pharmaceuticals EEC SARL 
Tel: +33 185149776 (FR) 
e-mail: neurim@neurim.com </p>
<p>United Kingdom (Northern Ireland) 
RAD Neurim Pharmaceuticals EEC SARL 
Tel: +33 185149776 (FR) 
e-mail: neurim@neurim.com </p>
<p>Denne indlægsseddel blev senest ændret MM/ÅÅÅÅ. </p>
<p>Andre informationskilder </p>
<p>Du kan finde yderligere oplysninger om dette lægemiddel på Det Europæiske Lægemiddelagenturs 
hjemmeside http://www.ema.europa.eu </p>         </div>"""      





                    
Instance: bundlepackageleaflet-en-9b714872ced428c978b15edf78a3a6b4
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for circadin Package Leaflet for language en"
Description: "ePI document Bundle for circadin Package Leaflet for language en"
Usage: #example


* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #en

// Composition
* entry[0].fullUrl = "Composition/composition-en-9b714872ced428c978b15edf78a3a6b4"
* entry[0].resource = composition-en-9b714872ced428c978b15edf78a3a6b4

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mp9b714872ced428c978b15edf78a3a6b4"
* entry[=].resource = mp9b714872ced428c978b15edf78a3a6b4
                            
                    
Instance: bundlepackageleaflet-da-9b714872ced428c978b15edf78a3a6b4
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for circadin Package Leaflet for language da"
Description: "ePI document Bundle for circadin Package Leaflet for language da"
Usage: #example


* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #da

// Composition
* entry[0].fullUrl = "Composition/composition-da-9b714872ced428c978b15edf78a3a6b4"
* entry[0].resource = composition-da-9b714872ced428c978b15edf78a3a6b4

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mp9b714872ced428c978b15edf78a3a6b4"
* entry[=].resource = mp9b714872ced428c978b15edf78a3a6b4
                            
                    



Instance: mp9b714872ced428c978b15edf78a3a6b4
InstanceOf: MedicinalProductDefinitionUvEpi
Title: "Medicinal Product Circadin 2 mg prolonged-release tablets"
Description: "Circadin 2 mg prolonged-release tablets"
Usage: #inline

 
* identifier[+].system = "http://ema.europa.eu/identifier"
* identifier[=].value = "EU/1/07/392/001"
* type = http://hl7.org/fhir/medicinal-product-type#MedicinalProduct "Medicinal Product"

* domain = http://hl7.org/fhir/medicinal-product-domain#Human "Human use"

* status = http://hl7.org/fhir/publication-status#active "active"



* legalStatusOfSupply = $spor-rms#100000072084 "Medicinal product subject to medical prescription"

* name
  * productName = "Circadin 2 mg prolonged-release tablets"
  * type = $spor-productNamePartType-cs#220000000001 "Full name" 
  
  * part[0]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000002 "Invented name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000003 "Scientific name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000004 "Strength part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000005 "Pharmaceutical dose form part"
  
  * usage
    * country = urn:iso:std:iso:3166#EU "EU"
    * jurisdiction = urn:iso:std:iso:3166#EU "EU"
    * language = urn:ietf:bcp:47#en  "en"



RuleSet: 9b714872ced428c978b15edf78a3a6b4ListRuleset

* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* identifier[+].system = "http://spor.ema.europa.eu/v2/medicine-name"
* identifier[=].value = "circadin"

* status = #current
* mode = #working

* title = "List of all ePIs associated with circadin"

* subject = Reference(mp61ab6e13a68691fed66e52cea007962f)
* subject.extension[0].url = "http://ema.europa.eu/fhir/extension/medicine-name"
* subject.extension[=].valueCoding = $100000000005#circadin "circadin"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/marketing-authorization-holder"
* subject.extension[=].valueCoding = $100000000005#mah-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/active-substance"
* subject.extension[=].valueCoding = $100000000005#acive-substance-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/domain"
* subject.extension[=].valueCoding = $100000000004#100000000012 "H"

* date = "2015-02-07T13:28:17Z"


* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-en-9b714872ced428c978b15edf78a3a6b4) // circadin en
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "en"



* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-da-9b714872ced428c978b15edf78a3a6b4) // circadin da
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "da"




Instance: List-9b714872ced428c978b15edf78a3a6b4
InstanceOf: List

* insert 9b714872ced428c978b15edf78a3a6b4ListRuleset
    